立康生命科技 Likang Life Sciences
Contact us

About Us

OVERVIEW

PERSONALIZED IMMUNITY REDEFINING POSSIBILITY

Likang Life Sciences is a clinical-stage biotechnology company developing personalized cancer immunotherapies. We integrate AI-assisted neoantigen identification, high-throughput sequencing, mRNA technology and dendritic cell–based antigen delivery to develop therapeutic vaccines tailored to each patient’s unique tumor profile.

LIKANG LIFE SCIENCES · SINCE 2017

↗Founded
↗Core Discovery Platform
↗Pipeline Programs
↗IND Clearances

OUR HISTORY

From Discovery To Global Clinical Progress.

Five milestones trace the evolution of Likang Life Sciences, from the establishment of its AI-powered discovery platform to regulatory and translational progress in personalized immunotherapy.

  1. 2017

    Likang Life Sciences Founded

    Beijing, China

  2. 2018

    LNEA Platform Established

    Proprietary AI-powered platform for tumor neoantigen analysis

  3. MAR, 2023

    China NMPA IND Clearance

    LK101

  4. FEB 2025

    U.S. FDA IND Clearance

    LK101

  5. APR 2025

    Hainan Boao Lecheng Translational Application Approval

    Covering 11 solid tumor indications

  1. 2017

    Likang Life Sciences Founded

    Beijing, China

  2. 2018

    LNEA Platform Established

    Proprietary AI-powered platform for tumor neoantigen analysis

  3. MAR, 2023

    China NMPA IND Clearance

    LK101

  4. FEB 2025

    U.S. FDA IND Clearance

    LK101

  5. APR 2025

    Hainan Boao Lecheng Translational Application Approval

    Covering 11 solid tumor indications

Our Team

Team member01 / 03
Chen Li, Ph.D.

Dr. Chen graduated from Beijing Institute of Technology, and then graduated from the Institute of Biophysics of the Chinese Academy of Sciences with a Ph.D.’s degree. He subsequently conducted postdoctoral research in clinical medicine at Peking University Cancer Hospital & Institute.

Chen Li, Ph.D.

Founder, Chairman and CEO